This company has been marked as potentially delisted and may not be actively trading. NASDAQ:KERX Keryx Biopharmaceuticals (KERX) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Keryx Biopharmaceuticals Stock (NASDAQ:KERX) 30 days 90 days 365 days Advanced Chart Get KERX alerts:Sign Up Key Stats Today's Range$2.97▼$3.4750-Day Range N/A52-Week Range$2.47▼$5.98Volume2.60 million shsAverage Volume1.69 million shsMarket Capitalization$344.00 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewKeryx Biopharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on providing medicines for patients with kidney disease in the United States. It markets its lead product Auryxia (ferric citrate), an orally available, absorbable, iron-based medicine for the control of serum phosphorus levels in patients with chronic kidney disease (CKD) on dialysis, as well as for the treatment of iron deficiency anemia in adults with CKD not on dialysis. The company has strategic alliances with Japan Tobacco Inc. and Torii Pharmaceutical Co., Ltd. for the development and commercialization of ferric citrate in Japan; and with Panion & BF Biotech, Inc. for the development and marketing of ferric citrate. Keryx Biopharmaceuticals, Inc. was founded in 1997 and is headquartered in Boston, Massachusetts.Read More… Receive KERX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Keryx Biopharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address KERX Stock News HeadlinesLBTI Lithium & Boron Technology, Inc.September 24, 2024 | seekingalpha.com2024 Biopharmaceutical Industry LandscapeAugust 17, 2024 | morningstar.comDonald Trump is about to free crypto from its chains …Sure enough, Bitcoin took off on the exact day Juan said it would. It's up more than 40% since the election … surpassing $100,000 on Dec. 8 .… Now Juan believes it could hit $150,000 … or higher in 2025.May 3, 2025 | Weiss Ratings (Ad)Caliway Biopharmaceuticals Co Ltd 6919April 13, 2024 | morningstar.comXTL Biopharmaceuticals Ltd ADR XTLBNovember 15, 2023 | morningstar.comImmuneOnco Biopharmaceuticals Shanghai Inc (1541)September 11, 2023 | investing.comQ2 2023 Westrock Coffee Co Earnings CallAugust 13, 2023 | finance.yahoo.comKeryx CEO vs. a Short-Seller: Zerenex Patent DebateJuly 29, 2023 | thestreet.comSee More Headlines KERX Stock Analysis - Frequently Asked Questions How were Keryx Biopharmaceuticals' earnings last quarter? Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) released its earnings results on Thursday, November, 8th. The biopharmaceutical company reported ($0.14) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.15) by $0.01. The biopharmaceutical company had revenue of $28.04 million for the quarter, compared to the consensus estimate of $29.56 million. What other stocks do shareholders of Keryx Biopharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Keryx Biopharmaceuticals investors own include Synergy Pharmaceuticals (SGYP), Bristol-Myers Squibb (BMY), Amyris (AMRS), Gilead Sciences (GILD), Exelixis (EXEL), Meta Platforms (META) and Immunomedics (IMMU). Company Calendar Last Earnings11/08/2018Today5/03/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryBiotechnology Current SymbolNASDAQ:KERX CIK1114220 Webwww.keryx.com Phone617-466-3500FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.88) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-163,440,000.00 Net Margins-96.41% Pretax MarginN/A Return on EquityN/A Return on Assets-60.05% Debt Debt-to-Equity RatioN/A Current Ratio2.21 Quick Ratio1.19 Sales & Book Value Annual Sales$60.64 million Price / Sales5.67 Cash FlowN/A Price / Cash FlowN/A Book Value($0.12) per share Price / Book-28.00Miscellaneous Outstanding Shares102,380,000Free FloatN/AMarket Cap$344.00 million OptionableOptionable Beta2.35 Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report This page (NASDAQ:KERX) was last updated on 5/3/2025 by MarketBeat.com Staff From Our PartnersElon’s Terrifying Warning Forces Trump To Take ActionElon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredTrump’s Bitcoin Reserve is No Accident…Bryce Paul believes this is the #1 coin to buy right now The catalyst behind this surge is a massive new b...Crypto 101 Media | SponsoredElon Set to Shock the World on June 1st?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredShocking AI play that’s beats Nvidia by a country mileYou’ve seen the headlines about Nvidia. Now Tim Sykes is sounding the alarm — because what CEO Jensen Huang is...Timothy Sykes | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | SponsoredWhat President Trump’s Executive Order 14154 means for your moneyNearly $3 trillion disappeared from the stock market on Thursday morning. According to Whitney Tilson - a f...Stansberry Research | SponsoredHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Keryx Biopharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Keryx Biopharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.